Identification of PARP-1 in cancer stem cells of gastrointestinal cancers: A preliminary study
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Identification of PARP-1 in cancer stem cells of gastrointestinal cancers: A preliminary study
Authors
Keywords
-
Journal
JOURNAL OF BIOSCIENCES
Volume 46, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-02-03
DOI
10.1007/s12038-020-00135-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2020
- (2020) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Cytoplasmic PARP-1 Promotes Pancreatic Cancer Tumorigenesis and Resistance
- (2019) Fei Xu et al. INTERNATIONAL JOURNAL OF CANCER
- Sensitization of colorectal cancer to irinotecan therapy by PARP inhibitor rucaparib
- (2019) Titto Augustine et al. INVESTIGATIONAL NEW DRUGS
- MiR-204 inhibits hepatocellular cancer drug resistance and metastasis through targeting NUAK1
- (2019) Yuhui Yu et al. Biochemistry and Cell Biology
- Targeting PARP and autophagy evoked synergistic lethality in hepatocellular carcinoma
- (2019) Wenjing Zai et al. CARCINOGENESIS
- Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer
- (2019) Talia Golan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combination Olaparib and Temozolomide in Relapsed Small-Cell Lung Cancer
- (2019) Anna F. Farago et al. Cancer Discovery
- ECOG performance score 0 versus 1: impact on efficacy and safety of first-line 5-FU-based chemotherapy among patients with metastatic colorectal cancer included in five randomized trials
- (2019) Omar Abdel-Rahman INTERNATIONAL JOURNAL OF COLORECTAL DISEASE
- The plasticity of pancreatic cancer metabolism in tumor progression and therapeutic resistance
- (2018) Douglas E. Biancur et al. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
- A phase 2 study of the PARP inhibitor veliparib plus temozolomide in patients with heavily pretreated metastatic colorectal cancer
- (2018) Michael J. Pishvaian et al. CANCER
- The PARP inhibitor olaparib potentiates the effect of the DNA damaging agent doxorubicin in osteosarcoma
- (2018) Hye Jeong Park et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- PARP-1 protects against colorectal tumor induction, but promotes inflammation-driven colorectal tumor progression
- (2018) Bastian Dörsam et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- PARP inhibitors synergize with gemcitabine by potentiating DNA damage in non-small-cell lung cancer
- (2018) Yu Jiang et al. INTERNATIONAL JOURNAL OF CANCER
- Drug resistance and new therapies in colorectal cancer
- (2018) Kevin Van der Jeught et al. WORLD JOURNAL OF GASTROENTEROLOGY
- PARP‐1 regulates DNA repair factor availability
- (2018) Matthew J Schiewer et al. EMBO Molecular Medicine
- Therapeutic Targeting of Poly(ADP-Ribose) Polymerase-1 (PARP1) in Cancer: Current Developments, Therapeutic Strategies, and Future Opportunities
- (2017) Jyotika Rajawat et al. MEDICINAL RESEARCH REVIEWS
- Colon Cancer
- (2017) Paul F. Engstrom et al. Journal of the National Comprehensive Cancer Network
- Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high grade serous ovarian and breast cancer
- (2016) U.A. Matulonis et al. ANNALS OF ONCOLOGY
- Cancer stem cells in human gastrointestinal cancer
- (2016) Hiroaki Taniguchi et al. CANCER SCIENCE
- Efficacy of poly (ADP-ribose) polymerase inhibitor olaparib against head and neck cancer cells: Predictions of drug sensitivity based on PAR–p53–NF-κB interactions
- (2016) Minsu Kwon et al. CELL CYCLE
- Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors
- (2016) P. M. LoRusso et al. CLINICAL CANCER RESEARCH
- Cell surface galectin-3 defines a subset of chemoresistant gastrointestinal tumor-initiating cancer cells with heightened stem cell characteristics
- (2016) Matthias Ilmer et al. Cell Death & Disease
- Aldehyde dehydrogenase 1A1 in stem cells and cancer
- (2016) Hiroyuki Tomita et al. Oncotarget
- Low adherent cancer cell subpopulations are enriched in tumorigenic and metastatic epithelial-to-mesenchymal transition-induced cancer stem-like cells
- (2016) Cynthia Morata-Tarifa et al. Scientific Reports
- A phase II study of weekly irinotecan in patients with locally advanced or metastatic HER2- negative breast cancer and increased copy numbers of the topoisomerase 1 (TOP1) gene: a study protocol
- (2015) Iben Kümler et al. BMC CANCER
- CHD1L Regulated PARP1-Driven Pluripotency and Chromatin Remodeling During the Early-Stage Cell Reprogramming
- (2015) Bo-Hua Jiang et al. STEM CELLS
- Doxorubicin-induced necrosis is mediated by poly-(ADP-ribose) polymerase 1 (PARP1) but is independent of p53
- (2015) Hyeon-Jun Shin et al. Scientific Reports
- The Cancer Stem Cell Marker Aldehyde Dehydrogenase Is Required to Maintain a Drug-Tolerant Tumor Cell Subpopulation
- (2014) D. Raha et al. CANCER RESEARCH
- Poly(ADP-Ribose) Polymerase 1 (PARP1) Overexpression in Human Breast Cancer Stem Cells and Resistance to Olaparib
- (2014) Marine Gilabert et al. PLoS One
- PARP-1 Expression is Increased in Colon Adenoma and Carcinoma and Correlates with OGG1
- (2014) Tomasz Dziaman et al. PLoS One
- Stem cells in gastrointestinal cancers: The road less travelled
- (2014) Sameh Mikhail World Journal of Stem Cells
- Therapeutic targeting of constitutive PARP activation compromises stem cell phenotype and survival of glioblastoma-initiating cells
- (2013) M Venere et al. CELL DEATH AND DIFFERENTIATION
- Checkpoint Signaling, Base Excision Repair, and PARP Promote Survival of Colon Cancer Cells Treated with 5-Fluorodeoxyuridine but Not 5-Fluorouracil
- (2011) Liyi Geng et al. PLoS One
- Insight into the Mechanism of Inactivation of Ribonucleotide Reductase by Gemcitabine 5′-Diphosphate in the Presence or Absence of Reductant
- (2009) Erin Artin et al. BIOCHEMISTRY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search